|
1.
|
|
|
2.
|
|
14 p, 1.1 MB |
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia
/
Kipps, Thomas J. (UC San Diego Moores Cancer Center) ;
Fraser, Graeme (McMaster University (Canadà)) ;
Coutre, Steven E (Stanford University School of Medicine) ;
Brown, Jennifer R. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Barrientos, Jacqueline C. (Northwell Health Cancer Institute) ;
Barr, Paul M. (University of Rochester) ;
Byrd, John C. (The Ohio State University Comprehensive Cancer Center) ;
O'Brien, Susan M. (University of California) ;
Dilhuydy, Marie-Sarah (Hôpital Haut-Lévêque) ;
Hillmen, Peter (University of Leeds) ;
Jaeger, Ulrich (Medical University of Vienna) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Cramer, Paula (University of Cologne) ;
Stilgenbauer, Stephan (University of Ulm) ;
Chanan-Khan, Asher A. (Mayo Clinic Cancer Center) ;
Mahler, Michelle (Janssen Research and Development) ;
Salman, Mariya (Janssen Research and Development) ;
Eckert, Karl (Pharmacyclics LLC. an AbbVie Company) ;
Solman, Isabelle G. (Pharmacyclics LLC. an AbbVie Company) ;
Balasubramanian, Sriram (Janssen Research and Development) ;
Cheng, Mei (Pharmacyclics LLC. an AbbVie Company) ;
Londhe, Anil (Janssen Research and Development) ;
Ninomoto, Joi (Pharmacyclics LLC. an AbbVie Company) ;
Howes, Angela (Janssen Research and Development) ;
James, Danelle F. (Pharmacyclics LLC. an AbbVie Company) ;
Hallek, Michael (University of Cologne) ;
Universitat Autònoma de Barcelona
Certain genomic features, such as del(11q), expression of unmutated immunoglobulin heavy-chain variable region (IGHV) gene, or complex karyotype, predict poorer outcomes to chemotherapy in patients with chronic lymphocytic leukemia (CLL). [...]
2019 -  10.1016/j.clml.2019.07.004
Clinical Lymphoma, Myeloma & Leukemia, Vol. 19 Núm. 11 (november 2019) , p. 715-722.e6
|
|
|
3.
|
|
13 p, 1.6 MB |
Refining Kidney Survival in 383 Genetically Characterized Patients With Nephronophthisis
/
König, Jens Christian (Department of General Pediatrics, University Children's Hospital Münster) ;
Karsay, Rebeka (Department of General Pediatrics, University Children's Hospital Münster) ;
Gerß, Joachim (Institute of Biostatistics and Clinical Research, University of Münster) ;
Schlingmann, Karl-Peter (Department of General Pediatrics, University Children's Hospital Münster) ;
Dahmer-Heath, Mareike (Department of General Pediatrics, University Children's Hospital Münster) ;
Telgmann, Anna-Katharina (Department of General Pediatrics, University Children's Hospital Münster) ;
Kollmann, Sabine (Department of General Pediatrics, University Children's Hospital Münster) ;
Ariceta Iraola, Gema (Hospital Universitari Vall d'Hebron) ;
Gillion, Valentine (Division of Nephrology, Saint-Luc Academic Hospital, Université Catholique Louvain) ;
Bockenhauer, Detlef (Great Ormond Street Hospital for Children (Londres)) ;
Bertholet-Thomas, Aurélia (Centre de Référence des Maladies Rénales Rares-Néphrogones-Hôpital Femme Mère Enfant, Hospices Civils de Lyon-Filière ORKiD) ;
Mastrangelo, Antonio (Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca' Granda Ospedale Maggiore Policlinico) ;
Boyer, Olivia (Hôpital Necker-Enfants Malades, Université de Paris) ;
Lilien, Marc (Department of Pediatric Nephrology, University Medical Center Utrecht) ;
Decramer, Stéphane (Université Toulouse III Paul-Sabatier) ;
Schanstra, Joost. P. (Université Toulouse III Paul-Sabatier) ;
Pohl, Martin (Department of Pediatrics, University Hospital Freiburg) ;
Schild, Raphael (University Medical Center Hamburg-Eppendorf) ;
Weber, Stefanie (University Children's Hospital) ;
Hoefele, Julia (Institut für Humangenetik) ;
Drube, Jens (Departement of Pediatric Nephrology, Medical School Hannover) ;
Cetiner, Metin (Department of Pediatric Nephrology, University of Duisburg-Essen) ;
Hansen, Matthias (Clementine Kinderhospital) ;
Thumfart, Julia (Charité - Universitätsmedizin Berlin) ;
Tönshoff, Burkhard (Department of Pediatrics I, University Children's Hospital Heidelberg) ;
Habbig, Sandra (Department of Pediatric, University of Cologne) ;
Liebau, Max Christoph (University Hospital Cologne and Medical) ;
Bald, Martin (Children's Hospital (Alemanya)) ;
Bergmann, Carsten (Medizinische Genetik Mainz (Alemanya)) ;
Pennekamp, Petra (Department of General Pediatrics, University Children's Hospital Münster) ;
Konrad, Martin (Department of General Pediatrics, University Children's Hospital Münster) ;
Universitat Autònoma de Barcelona
Nephronophthisis (NPH) comprises a group of rare disorders accounting for up to 10% of end-stage kidney disease (ESKD) in children. Prediction of kidney prognosis poses a major challenge. We assessed differences in kidney survival, impact of variant type, and the association of clinical characteristics with declining kidney function. [...]
2022 - 10.1016/j.ekir.2022.05.035
Kidney International Reports, Vol. 7 (june 2022) , p. 2016-2028
|
|
|
4.
|
|
13 p, 2.4 MB |
Initial clinical and treatment patterns of advanced differentiated thyroid cancer : ERUDIT study
/
Vallejo Casas, Juan Antonio (Insituto Maimónides de Investigación Biomédica (Córdoba)) ;
Sambo, Marcel (Hospital General Universitario Gregorio Marañón) ;
López-López, Carlos A (Instituto de Investigación Marqués de Valdecilla) ;
Durán-Poveda, Manuel (Hospital Universitario Rey Juan Carlos (Madrid)) ;
Rodríguez-Villanueva García, Julio (EISAI Farmacéutica SA) ;
Santos, Rita Joana (Department of Endocrinology. Francisco Gentil Portuguese Institute of Oncology of Lisbon) ;
Llanos, Marta (Hospital Universitario de Canarias (La Laguna)) ;
Navarro-González, Elena (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Aller, Javier (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Pubul, Virginia (Hospital Universitario Santiago de Compostela) ;
Guadalix, Sonsoles (Hospital Universitario 12 de Octubre (Madrid)) ;
Crespo, Guillermo (Hospital Universitario de Burgos) ;
González, Cintia (Institut d'Investigació Biomèdica Sant Pau) ;
Zafón, Carles (Hospital Universitari Vall d'Hebron) ;
Navarro, Miguel (Hospital Universitario de Salamanca) ;
Santamaría-Sandi, Javier (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Segura, Ángel (Hospital Universitari i Politècnic La Fe (València)) ;
Gajate, Pablo (Hospital Universitario Ramón y Cajal (Madrid)) ;
Gómez-Balaguer, Marcelino (Hospital Universitari Doctor Peset (València)) ;
Valdivia, Javier (Hospital Universitario Virgen de las Nieves (Granada)) ;
Puig-Domingo, Manel (Institut Germans Trias i Pujol) ;
Galofré, Juan C (Hospital Universitario de Navarra) ;
Castelo, Beatriz (Hospital Universitario La Paz (Madrid)) ;
Villanueva, María José (Hospital Universitario de Vigo) ;
Argüelles, Iñaki (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Orcajo-Rincón, Lorenzo (EISAI Farmacéutica SA) ;
Universitat Autònoma de Barcelona
Background: Up to 30% of differentiated thyroid cancer (DTC) will develop advanced-stage disease (aDTC) with reduced overall survival (OS). Objective: The aim of this study is to characterize initial diagnosis of aDTC, its therapeutic management, and prognosis in Spain and Portugal. [...]
2022 - 10.1530/ETJ-21-0111
European Thyroid Journal, Vol. 11 Núm. 5 (october 2022) , p. e210111
|
|
|
5.
|
|
14 p, 6.0 MB |
The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial
/
Ayala, Rosa (Centro de Investigación Biomédica en Red de Cáncer) ;
Rapado, Inmaculada (Centro de Investigación Biomédica en Red de Cáncer) ;
Onecha, Esther (Hematological Malignancies Clinical Research Unit (Madrid)) ;
Martínez-Cuadrón, David (Hospital Universitari i Politècnic La Fe (València)) ;
Carreño-Tarragona, Gonzalo (Hematological Malignancies Clinical Research Unit (Madrid)) ;
Bergua Burgues, Juan Miguel (Hospital San Pedro de Alcántara) ;
Vives Polo, Susana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Algarra Algarra, Jesus Lorenzo (Complejo Hospitalario Universitario de Albacete) ;
Tormo, Mar (Hospital Clínic Universitari (València)) ;
Martinez, Pilar (Hospital Universitario 12 de Octubre (Madrid)) ;
Serrano, Josefina (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Herrera, Pilar (Hospital Universitario Ramon y Cajal (Madrid)) ;
Ramos, Fernando (Hospital Universitario de León) ;
Salamero, Olga (Hospital Universitari Vall d'Hebron) ;
Lavilla, Esperanza (Hospital Universitario Xeral de Lugo) ;
Gil, Cristina (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
López Lorenzo, Jose Luis (Hematology Department, Fundación Jiménez Díaz (Madrid)) ;
Vidriales, María Belén (Instituto de Investigación Biomédica de Salamanca) ;
Labrador, Jorge (Hospital Universitario de Burgos) ;
Falantes, José Francisco (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Sayas, María José (Hospital Universitari Doctor Peset (València)) ;
Paiva, Bruno (Clínica Universidad de Navarra) ;
Barragán, Eva (Hospital Universitari i Politècnic La Fe (València)) ;
Prosper, Felipe (Clínica Universidad de Navarra) ;
Sanz, Miguel A.. (Hospital Universitari i Politècnic La Fe (València)) ;
Martínez-López, Joaquín (Centro de Investigación Biomédica en Red de Cáncer) ;
Montesinos, Pau (Hospital Universitari i Politècnic La Fe (València)) ;
Universitat Autònoma de Barcelona
Mutational profiling using a custom 43-gene next-generation sequencing panel revealed that patients with mutated DNMT3A or EZH2, or an increase in TET2 VAF and lower TP53 VAF showed a higher overall response. [...]
2021 - 10.3390/cancers13102458
Cancers, Vol. 13 (may 2021)
|
|
|
6.
|
|
15 p, 2.2 MB |
Efficacy and Safety of the Combination of Pravastatin and Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (ESTAHEP Clinical Trial)
/
Riaño, Ioana (Biodonostia Osasun Ikerketako Institutura (País Basc)) ;
Martín, Leticia (Biodonostia Osasun Ikerketako Institutura (País Basc)) ;
Varela Calvo, Maria (Hospital Universitario Central de Asturias) ;
Serrano, Trinidad (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Núñez, Oscar (Hospital Universitario Infanta Sofía (San Sebastián de los Reyes)) ;
Mínguez Rosique, Beatriz (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Rodrigues, Pedro M. (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ;
Perugorria, Maria J. (Universidad del País Vasco) ;
Banales, Jesus (Basque Foundation for Science) ;
Arenas, Joaquín (Biodonostia Osasun Ikerketako Institutura (País Basc)) ;
Universitat Autònoma de Barcelona
Pravastatin has demonstrated anti-tumor activity in preclinical and clinical studies. This multicentric randomized double-blind placebo-controlled phase II study (NCT01418729) investigated the efficacy and safety of sorafenib + pravastatin combination on the overall survival (OS) and time to progression (TTP) of patients with advanced hepatocellular carcinoma (aHCC). [...]
2020 - 10.3390/cancers12071900
Cancers, Vol. 12 (july 2020)
|
|
|
7.
|
|
14 p, 3.0 MB |
Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival
/
Cabezón, Marta (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Malinverni, Roberto (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bargay, Joan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Marcé, Silvia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Garrido, Ana (Institut d'Investigació Biomèdica Sant Pau) ;
Tormo, M. (Hospital Clínic Universitari (València)) ;
Arenillas, Leonor (Hospital del Mar (Barcelona, Catalunya)) ;
Coll, Rosa (Hospital Universitari de Girona Doctor Josep Trueta) ;
Borrás, Josep (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Jiménez, María José (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Hoyos Colell, Montserrat (Institut d'Investigació Biomèdica Sant Pau) ;
Valcárcel, David (Hospital Universitari Vall d'Hebron) ;
Escoda, Lourdes (Hospital Universitari Joan XXIII de Tarragona) ;
Vall-Llovera, Ferran (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Garcia, A. (Hospital Arnau de Vilanova (Lleida, Catalunya)) ;
Font, L. L. (Hospital de Tortosa Verge de la Cinta) ;
Ramila, Elena (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Buschbeck, Marcus (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Zamora, Lurdes (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Epigenetic therapy, using hypomethylating agents (HMA), is known to be effective in the treatment of high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) patients who are not suitable for intensive chemotherapy and/or allogeneic stem cell transplantation. [...]
2021 - 10.1186/s13148-021-01002-y
Clinical Epigenetics, Vol. 13 (january 2021)
|
|
|
8.
|
|
11 p, 991.3 KB |
Short-term mortality in end-stage heart failure patients
/
Verdú-Rotellar, Jose Maria (Institut Universitari d'Investigació en Atenció Primària Jordi Gol) ;
Calero, Esther (Institut Universitari d'Investigació en Atenció Primària Jordi Gol) ;
Abellana, Rosa (Institut Universitari d'Investigació en Atenció Primària Jordi Gol) ;
Verdú-Soriano, José (Universitat d'Alacant) ;
Vinyoles, Ernest (Institut Universitari d'Investigació en Atenció Primària Jordi Gol) ;
Del Val García, José Luis ;
Domingo, Mar (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Muñoz, Miguel-Angel (Institut Universitari d'Investigació en Atenció Primària Jordi Gol) ;
Universitat Autònoma de Barcelona
This study is aimed at analyzing the impact of the main factors contributing to short and long-term mortality in patients at final stages of heart failure (HF). Patients attended at any of the 279 primary health care centers belonging to the Institut Català de la Salut, in Catalonia (Spain). [...]
2020 - 10.1016/j.aprim.2019.07.019
Atencion Primaria, Vol. 52 (january 2020) , p. 477-487
|
|
|
9.
|
|
14 p, 1.9 MB |
Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine
/
Cabezón, Marta (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Bargay, Joan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Xicoy, Blanca (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
García, Olga (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Borrás, Josep (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Tormo, Mar (Hospital Clínic Universitari (València)) ;
Marcé, Silvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Pedro, Carme (Hospital del Mar (Barcelona, Catalunya)) ;
Valcárcel, David (Hospital Universitari Vall d'Hebron) ;
Jiménez, Maria José (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Guàrdia, Ramón (Hospital Universitari de Girona Doctor Josep Trueta) ;
Palomo Sanchís, Laura (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Brunet, Salut (Institut d'Investigació Biomèdica Sant Pau) ;
Vall-Llovera, Ferran (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Garcia, Antoni (Hospital Arnau de Vilanova (Lleida, Catalunya)) ;
Feliu Frasnedo, Evarist (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Zamora, Lurdes (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Universitat Autònoma de Barcelona
Myelodysplastic syndromes (MDS) are stem cell disorders caused by various gene abnormalities. We performed targeted deep sequencing in 39 patients with high-risk MDS and secondary acute myeloid leukemia (sAML) at diagnosis and follow-up (response and/or relapse), with the aim to define their mutational status, to establish if specific mutations are biomarkers of response to 5-azacytidine (AZA) and/or may have impact on survival. [...]
2018 - 10.18632/oncotarget.25046
Oncotarget, Vol. 9 (april 2018) , p. 19342-19355
|
|
|
10.
|
|
15 p, 2.2 MB |
Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features
/
Palomo Sanchís, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
García, Olga (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Arnan, Montserrat (Institut Català d'Oncologia) ;
Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Fuster García, Francisco (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Cabezón, Marta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Coll, Rosa (Hospital Universitari de Girona Doctor Josep Trueta) ;
Ademà, Vera (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Grau Cat, Javier (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Jiménez, Maria-José (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Pomares, Helena (Institut Català d'Oncologia) ;
Marcé, Silvia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Mallo, Maria del Mar (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Millá, Fuensanta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Alonso, Esther (Institut Català d'Oncologia) ;
Sureda, Anna (Institut Català d'Oncologia) ;
Gallardo, David (Hospital Universitari de Girona Doctor Josep Trueta) ;
Feliu Frasnedo, Evarist (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Sole, F (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Zamora, Lurdes (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Clonal cytogenetic abnormalities are found in 20-30% of patients with chronic myelomonocytic leukemia (CMML), while gene mutations are present in >90% of cases. Patients with low risk cytogenetic features account for 80% of CMML cases and often fall into the low risk categories of CMML prognostic scoring systems, but the outcome differs considerably among them. [...]
2016 - 10.18632/oncotarget.10937
Oncotarget, Vol. 7, Num. 35 (August 2016) , p. 57021-57035
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
